Log In
Print this Print this

Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50-based gene expression test for breast cancer)

Also known as: NanoString Breast Cancer Intrinsic Subtyping Assay

  Manage Alerts
Collapse Summary General Information
Company NanoString Technologies Inc.
DescriptionBreast cancer intrinsic subtyping assay that runs on the nCounter Analysis System and uses the PAM50 gene signature
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetermine risk of breast cancer recurrence
Regulatory Designation Canada - Standard Review (Determine risk of breast cancer recurrence)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today